On August 25, Henan Jufeel Technology Co., LTD. (hereinafter referred to as Jufeel) signed the listed signed strategic cooperation with Beijing Ruige Laishi Biotechnology Co., LTD. (hereinafter referred to as Ruige Laishi), two parties reach an agreement on the reasonable integration of Ruige Laishi's ERC cell(endometrium - derived blood vessels stimulate cells, the US patent application no. : 16282316) practical technology and current business into the overseas listed company of Jufeel.

　　The two parties agree to jointly initiate the establishment of a new project company with a total equity of RMB 750 million, with 51% of the shares held by the two parties as joint action persons.

　　After the signing of the agreement, Jufeel will inject capital into Ruige Laishi for the construction of its scientific research platform, and will employ the Nobel Prize winner as the expert consultant of the institute; build laboratories with high standards and pass the national GMP or related industry certification; establish scientific research and production team, optimize production process, reduce cell production cost, and rapidly promote clinical transformation and application of biological cell technology. At present, the main technical team leader of this project is Li Fei, M.D. of People's Liberation Army General Hospital (301 Hospital), a leading expert of global reproductive stem cell technology.

　　Li Fei, Master of Clinical Medicine, Jilin University; Doctor of Nephrology, People's Liberation Army General Hospital (301 Hospital); guest Professor of Beihua University, fellow of Academician Chen Xiangmei. From 2000 to 2003, he worked in the nephrosis internal medicine department of 301 Hospital, engaged in clinical diagnosis and basic research in biotechnology, and later served as medical director of Hong Kong Pacific Medical Management Group. Currently, Li Fei is the chief medical technology officer of Beilian Meiou Biotechnology Co., Ltd., the executive director of the China Nobel Prize Winners Summit Forum Organizing Committee, the executive director of the Foreign Exchange and Technical Cooperation Department of the China Science and Technology Industry Association, and the executive director of the Technical Innovation and Application Branch of the China Anti-Aging Promoting Association.

　　Dr. Li Fei has been engaged in the research of biotechnology in the field of anti-aging since 2003. His main research direction is individual comprehensive rejuvenation and sexual health. The main research content is the mechanism of action of biological cells in the field of anti-aging and chronic disease management. He began to research the IMC series products from 2010, and participate in the research and application of genetic testing and biological immune cell therapy technology. His R&D results IMC active cell subcutaneous injection technology, ERC male donor stem cell microinjection technology has been successfully clinically transformed. And he created the biological diagnosis and treatment technology system with complete" intelligent micro-shaping "and" precise rejuvenation management ", and achieved the safety and efficacy beyond the traditional technology, which has been recognized by the medical community.

　　In view of the male with sexual dysfunction, short penis, hypoactive sexual desire, poor sperm quality and quantity,etc., using the stem cell's self-replication and the differentiation potential to repair the normal function of damaged organs and tissues. After using it, patients become healthier, younger and more active as the new cells act like normal testicular cells to produce androgen.

　　For menopausal syndrome, insufficient estrogen secretion level, thinning or damage of endometrium, vaginal relaxation or decreased sensitivity and other problems, stem cell reinfusion therapy is performed by extracting stem cells of high quantity and quality and reinfusing them to patients via vein. Using automatic homing of stem cells, that is the stem cells will be automatically transferred to the damaged lesions in the human body, nourish and repair the pathological ovarian cells, regulate and secrete the female hormones, improve the quality of sexual life, to bring good news for women patients like menopause and infertility caused by ovarian premature, promote healthy reproduction and body, keep young body, say goodbye to out of shape, solve the problem of a series of gynaecological matters, improve the ability of the reproductive system.

　　All the cell testing projects of Ruige Laishi have superior safety quality. It not only has a number of invention patent certificates, and ensures that each batch of cells hit the target according to international and national standards, the inspection report has been reviewed by third-party inspection institutions according to the self-inspection procedures of the quality control department of the R&D center.

　　According to the agreement between the two parties, the key R&D center to be established will be settled in the second life and health industry innovation demonstration zone, Beidaihe life and health industry innovation demonstration zone new area, following the Hainan Boao Medical Tourism Pioneer Zone. The R&D center focuses on the R&D of the core technology system of “stem cell reproduction and anti-aging”. In addition to Dr. Li Fei, there are many Nobel Prize winners, international experts, Chinese academicians, professors and other core experts in the R&D center, such as American biologist K. Szostak, who has taught at Harvard Medical school since 1979, and won the 2009 Nobel Prize in physiology or medicine for discovering how telomeres and telomerase protect cells' chromosomes; and Dr. Lin Feng, Doctor of medicine, Xiangya medical college, Central South University, former R&D director of Entest biomedical company, senior scientist of US Inovio Pharmaceutical Company (NYSE: INO). He has obtained three patents in the United States to develop the new technology of DNA delivery and its application in the R&D of DNA vaccines for treating cancer and chronic infectious diseases, and has successfully launched three products into clinical trials.

　　Medical beauty high-end products of Ruige Laishi will quickly capture market share by virtue of Jufeel’s mature sales system and strong capital operation ability to achieve the financial profit of the company set up by two parties, becoming the leading enterprise in the field of stem cells used in sexual reproduction. It will activate the health source by reproduction and anti-aging to let human beings have overall healthy.